Kiora Total Current Liabilities vs Net Debt Analysis

KPRX Stock

USD 3.25 0.10 2.99%

Kiora Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Kiora Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kiora Pharmaceuticals is a good investment. Please check the relationship between Kiora Pharmaceuticals Total Current Liabilities and its Net Debt accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.

Total Current Liabilities vs Net Debt

Total Current Liabilities vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kiora Pharmaceuticals Total Current Liabilities account and Net Debt. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Kiora Pharmaceuticals' Total Current Liabilities and Net Debt is -0.34. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Net Debt in the same time period over historical financial statements of Kiora Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Kiora Pharmaceuticals' Total Current Liabilities and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Kiora Pharmaceuticals are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Total Current Liabilities i.e., Kiora Pharmaceuticals' Total Current Liabilities and Net Debt go up and down completely randomly.

Correlation Coefficient

-0.34

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on Kiora Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Kiora Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from Kiora Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kiora Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.At this time, Kiora Pharmaceuticals' Tax Provision is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 8.7 M in 2025, whereas Selling General Administrative is likely to drop slightly above 4.8 M in 2025.

Kiora Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Intangible Assets	Other Liab	Net Tangible Assets
Total Assets		-0.49	0.86	0.18	0.93	0.75	-0.63	-0.86	0.28	0.62	0.88	-0.52	0.62	0.47	0.61	-0.88	0.72	0.94	-0.88	0.75	-0.49	0.48	0.46	0.64	0.68	0.76
Short Long Term Debt Total	-0.49		-0.55	0.06	-0.55	-0.27	0.67	0.35	-0.02	-0.51	-0.31	0.76	-0.51	-0.24	-0.24	0.52	-0.33	-0.43	0.56	-0.55	1.0	-0.3	-0.29	-0.16	-0.23	-0.31
Other Current Liab	0.86	-0.55		0.41	0.83	0.54	-0.57	-0.73	0.59	0.54	0.75	-0.53	0.54	0.45	0.59	-0.85	0.52	0.81	-0.78	0.66	-0.54	0.31	0.63	0.55	0.52	0.52
Total Current Liabilities	0.18	0.06	0.41		0.13	-0.08	-0.34	0.07	0.58	0.38	0.02	0.25	0.38	-0.26	-0.24	-0.32	0.24	0.02	-0.1	0.32	0.07	0.32	0.84	-0.24	-0.32	-0.33
Total Stockholder Equity	0.93	-0.55	0.83	0.13		0.58	-0.65	-0.81	0.28	0.65	0.77	-0.61	0.65	0.49	0.53	-0.97	0.66	0.89	-0.99	0.76	-0.56	0.5	0.41	0.46	0.59	0.72
Property Plant And Equipment Net	0.75	-0.27	0.54	-0.08	0.58		-0.46	-0.72	0.08	0.48	0.62	-0.35	0.48	0.49	0.63	-0.47	0.71	0.71	-0.5	0.61	-0.26	0.17	0.14	0.68	0.72	0.7
Net Debt	-0.63	0.67	-0.57	-0.34	-0.65	-0.46		0.28	-0.16	-0.96	-0.22	0.49	-0.96	-0.04	-0.06	0.68	-0.58	-0.43	0.65	-0.94	0.65	-0.6	-0.45	0.02	-0.03	-0.23
Retained Earnings	-0.86	0.35	-0.73	0.07	-0.81	-0.72	0.28		-0.11	-0.31	-0.86	0.48	-0.31	-0.75	-0.86	0.71	-0.55	-0.93	0.74	-0.49	0.35	-0.26	-0.31	-0.75	-0.9	-0.92
Accounts Payable	0.28	-0.02	0.59	0.58	0.28	0.08	-0.16	-0.11		0.16	0.27	0.1	0.16	-0.04	0.08	-0.39	0.15	0.19	-0.27	0.17	-0.01	-0.05	0.38	0.15	-0.02	-0.14
Cash	0.62	-0.51	0.54	0.38	0.65	0.48	-0.96	-0.31	0.16		0.2	-0.38	1.0	0.12	0.12	-0.68	0.6	0.41	-0.63	0.97	-0.49	0.64	0.49	-0.02	0.08	0.28
Non Current Assets Total	0.88	-0.31	0.75	0.02	0.77	0.62	-0.22	-0.86	0.27	0.2		-0.41	0.2	0.44	0.64	-0.7	0.59	0.9	-0.71	0.35	-0.32	0.25	0.3	0.78	0.77	0.76
Non Currrent Assets Other	-0.52	0.76	-0.53	0.25	-0.61	-0.35	0.49	0.48	0.1	-0.38	-0.41		-0.38	-0.38	-0.37	0.54	-0.32	-0.53	0.63	-0.46	0.77	-0.26	-0.09	-0.31	-0.4	-0.47
Cash And Short Term Investments	0.62	-0.51	0.54	0.38	0.65	0.48	-0.96	-0.31	0.16	1.0	0.2	-0.38		0.12	0.12	-0.68	0.6	0.41	-0.63	0.97	-0.49	0.64	0.49	-0.02	0.08	0.28
Net Receivables	0.47	-0.24	0.45	-0.26	0.49	0.49	-0.04	-0.75	-0.04	0.12	0.44	-0.38	0.12		0.9	-0.36	0.03	0.62	-0.43	0.32	-0.25	-0.01	0.08	0.67	0.82	0.72
Common Stock Shares Outstanding	0.61	-0.24	0.59	-0.24	0.53	0.63	-0.06	-0.86	0.08	0.12	0.64	-0.37	0.12	0.9		-0.39	0.17	0.72	-0.45	0.31	-0.23	-0.02	0.09	0.81	0.9	0.84
Non Current Liabilities Total	-0.88	0.52	-0.85	-0.32	-0.97	-0.47	0.68	0.71	-0.39	-0.68	-0.7	0.54	-0.68	-0.36	-0.39		-0.64	-0.83	0.97	-0.77	0.52	-0.55	-0.53	-0.32	-0.42	-0.57
Other Current Assets	0.72	-0.33	0.52	0.24	0.66	0.71	-0.58	-0.55	0.15	0.6	0.59	-0.32	0.6	0.03	0.17	-0.64		0.6	-0.6	0.61	-0.33	0.44	0.46	0.25	0.39	0.49
Other Stockholder Equity	0.94	-0.43	0.81	0.02	0.89	0.71	-0.43	-0.93	0.19	0.41	0.9	-0.53	0.41	0.62	0.72	-0.83	0.6		-0.86	0.59	-0.44	0.36	0.32	0.69	0.77	0.84
Total Liab	-0.88	0.56	-0.78	-0.1	-0.99	-0.5	0.65	0.74	-0.27	-0.63	-0.71	0.63	-0.63	-0.43	-0.45	0.97	-0.6	-0.86		-0.74	0.56	-0.49	-0.34	-0.38	-0.5	-0.65
Total Current Assets	0.75	-0.55	0.66	0.32	0.76	0.61	-0.94	-0.49	0.17	0.97	0.35	-0.46	0.97	0.32	0.31	-0.77	0.61	0.59	-0.74		-0.53	0.61	0.48	0.17	0.27	0.44
Short Term Debt	-0.49	1.0	-0.54	0.07	-0.56	-0.26	0.65	0.35	-0.01	-0.49	-0.32	0.77	-0.49	-0.25	-0.23	0.52	-0.33	-0.44	0.56	-0.53		-0.3	-0.29	-0.16	-0.24	-0.31
Common Stock	0.48	-0.3	0.31	0.32	0.5	0.17	-0.6	-0.26	-0.05	0.64	0.25	-0.26	0.64	-0.01	-0.02	-0.55	0.44	0.36	-0.49	0.61	-0.3		0.37	-0.18	-0.01	0.33
Current Deferred Revenue	0.46	-0.29	0.63	0.84	0.41	0.14	-0.45	-0.31	0.38	0.49	0.3	-0.09	0.49	0.08	0.09	-0.53	0.46	0.32	-0.34	0.48	-0.29	0.37		0.02	0.07	0.05
Intangible Assets	0.64	-0.16	0.55	-0.24	0.46	0.68	0.02	-0.75	0.15	-0.02	0.78	-0.31	-0.02	0.67	0.81	-0.32	0.25	0.69	-0.38	0.17	-0.16	-0.18	0.02		0.9	0.66
Other Liab	0.68	-0.23	0.52	-0.32	0.59	0.72	-0.03	-0.9	-0.02	0.08	0.77	-0.4	0.08	0.82	0.9	-0.42	0.39	0.77	-0.5	0.27	-0.24	-0.01	0.07	0.9		0.87
Net Tangible Assets	0.76	-0.31	0.52	-0.33	0.72	0.7	-0.23	-0.92	-0.14	0.28	0.76	-0.47	0.28	0.72	0.84	-0.57	0.49	0.84	-0.65	0.44	-0.31	0.33	0.05	0.66	0.87

Click cells to compare fundamentals

Kiora Pharmaceuticals Account Relationship Matchups

Kiora Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	15.2M	18.1M	18.7M	13.7M	15.8M	11.7M
Short Long Term Debt Total	362.1K	209.4K	105.8K	106.9K	96.2K	91.4K
Other Current Liab	1.3M	1.2M	2.1M	1.4M	1.6M	1.3M
Total Current Liabilities	1.8M	1.6M	3.3M	1.6M	1.5M	1.4M
Total Stockholder Equity	7.0M	9.2M	11.4M	6.1M	7.0M	7.4M
Property Plant And Equipment Net	30.6K	283.4K	172.2K	115.0K	132.2K	76.8K
Net Debt	(823.6K)	(7.6M)	(5.9M)	(2.3M)	(2.1M)	(2.2M)
Retained Earnings	(108.3M)	(124.7M)	(134.5M)	(147.0M)	(132.3M)	(138.9M)
Accounts Payable	434.8K	160.6K	1.0M	206.3K	237.2K	225.3K
Cash	1.2M	7.9M	6.0M	2.5M	2.8M	4.7M
Non Current Assets Total	13.3M	9.1M	11.0M	9.0M	10.3M	6.1M
Non Currrent Assets Other	102.1K	88.0K	82.3K	45.0K	40.5K	38.5K
Cash And Short Term Investments	1.2M	7.9M	6.0M	2.5M	2.8M	4.7M
Net Receivables	91.0K	529.6K	1.4M	2.0M	2.4M	2.5M
Common Stock Shares Outstanding	114.8K	241.1K	732.3K	538.0K	618.7K	649.6K
Liabilities And Stockholders Equity	15.2M	18.1M	18.7M	13.7M	15.8M	11.7M
Non Current Liabilities Total	6.4M	7.2M	4.0M	6.0M	5.4M	10.2M
Other Current Assets	449.6K	1.2M	343.1K	233.4K	268.4K	416.6K
Other Stockholder Equity	116.8M	135.4M	146.0M	153.2M	176.2M	93.4M
Total Liab	8.2M	8.8M	7.3M	7.6M	6.8M	12.5M
Total Current Assets	1.8M	9.0M	7.7M	4.7M	5.4M	5.6M
Accumulated Other Comprehensive Income	(802.0)	(86.4K)	(182.7K)	(182.8K)	(164.5K)	(156.3K)
Short Term Debt	260.6K	237.7K	211.6K	47.1K	42.4K	40.2K
Common Stock	55.6K	126.6K	18.0K	77.1K	88.6K	101.9K
Intangible Assets	9.7M	8.7M	10.7M	8.8M	10.1M	7.9M
Other Liab	1.5M	2.1M	6.1M	7.1M	8.2M	8.6M
Net Tangible Assets	7.2M	4.9M	3.3M	9.1M	10.4M	10.9M
Other Assets	4.0M	4.0M	0.0	1.0	0.9	0.86
Capital Lease Obligations	83.9K	209.4K	105.8K	106.9K	122.9K	96.0K
Net Invested Capital	7.3M	9.2M	11.4M	6.1M	7.0M	7.5M
Non Current Liabilities Other	5.3M	6.5M	3.3M	5.1M	5.9M	3.8M
Net Working Capital	37.8K	7.4M	4.4M	3.1M	3.6M	2.5M
Property Plant Equipment	43.5K	16.8K	30.6K	283.4K	325.9K	342.2K
Capital Stock	55.6K	126.6K	18.0K	77.1K	69.4K	100.8K
Property Plant And Equipment Gross	123.5K	396.5K	289.5K	121.2K	139.4K	226.7K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for Kiora Stock Analysis

When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kiora Total Current Liabilities vs Net Debt Analysis

Total Current Liabilities vs Net Debt

Total Current Liabilities vs Net Debt Correlation Analysis

Correlation Coefficient

Total Current Liabilities

Net Debt

Kiora Pharmaceuticals fundamental ratios Correlations

Kiora Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kiora Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Kiora Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Term Debt	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.97	Cash
Total Current Assets	+ 0.97	Cash And Short Term Investments
Total Liab	+ 0.97	Non Current Liabilities Total
Other Stockholder Equity	+ 0.94	Total Assets

Total Liab	- 0.99	Total Stockholder Equity
Non Current Liabilities Total	- 0.97	Total Stockholder Equity
Cash And Short Term Investments	- 0.96	Net Debt
Cash	- 0.96	Net Debt
Total Current Assets	- 0.94	Net Debt
Other Stockholder Equity	- 0.93	Retained Earnings